## Karen Y Oh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1628474/publications.pdf Version: 2024-02-01



Κλάξεν Υ Ομ

#	Article	IF	CITATIONS
1	Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology, 2018, 289, 618-627.	7.3	189
2	Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702). Clinical Cancer Research, 2019, 25, 1756-1765.	7.0	100
3	Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI. Translational Oncology, 2016, 9, 8-17.	3.7	94
4	Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy. Cancer Prevention Research, 2015, 8, 1184-1191.	1.5	83
5	Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. Journal of Magnetic Resonance Imaging, 2019, 49, 1617-1628.	3.4	76
6	Gadolinium Chelate Contrast Material in Pregnancy: Fetal Biodistribution in the Nonhuman Primate. Radiology, 2015, 276, 110-118.	7.3	63
7	DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response. Tomography, 2017, 3, 23-32.	1.8	56
8	Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure. Radiology, 2018, 286, 122-128.	7.3	42
9	Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. Npj Breast Cancer, 2020, 6, 63.	5.2	30
10	Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial. Radiology, 2021, 298, 60-70.	7.3	30
11	Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology, 2021, 301, 295-308.	7.3	17
12	Diagnostic accuracy and clinical outcomes associated with prenatal diagnosis of fetal absent cavum septi pellucidi. Prenatal Diagnosis, 2018, 38, 395-401.	2.3	16
13	Prenatal Diagnosis of Renal Developmental Anomalies Associated With an Empty Renal Fossa. Ultrasound Quarterly, 2010, 26, 233-240.	0.8	13
14	Unilateral Short Femur-What Does This Mean?. Ultrasound Quarterly, 2008, 24, 89-92.	0.8	12
15	Asymmetric Ventriculomegaly, Interhemispheric Cyst, and Dysgenesis of the Corpus Callosum (AVID). Journal of Ultrasound in Medicine, 2012, 31, 1811-1820.	1.7	12
16	Discrimination of Malignant and Benign Breast Lesions Using Quantitative Multiparametric MRI: A Preliminary Study. Tomography, 2020, 6, 148-159.	1.8	12
17	Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702). Journal of Breast Imaging, 2021, 3, 44-56.	1.3	10
18	Fetal Hepatomegaly: Causes and Associations. Radiographics, 2020, 40, 589-604.	3.3	9

Karen Y Oh

#	Article	IF	CITATIONS
19	Clinical outcomes following prenatal diagnosis of asymmetric ventriculomegaly, interhemispheric cyst, and callosal dysgenesis (AVID). Prenatal Diagnosis, 2019, 39, 26-32.	2.3	6
20	Intrauterine Linear Echogenicities in the Gravid Uterus: What Radiologists Should Know. Radiographics, 2018, 38, 642-657.	3.3	4
21	Adenomyosis in Pregnancy: Diagnostic Pearls and Pitfalls. Radiographics, 2021, 41, 929-944.	3.3	1